Alnylam reports positive kardia-2 topline study results demonstrating clinically significant blood pressure reductions when zilebesiran is added to standard of care antihypertensives

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the kardia-2 phase 2 study of zilebesiran, an investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension, met the primary endpoint showing that zilebesiran resulted in clinically and statistically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure.
ALNY Ratings Summary
ALNY Quant Ranking